about the author

ENDPOINTS

editor@endpointsnews.com

author articles

News wrap: Equi­l­li­um ax­es Metacrine merg­er; Two phar­mas pen ADC deals

3 years ago
News Briefing

Spe­cial re­port 2022: Meet 20 women blaz­ing trails in bio­phar­ma R&D

3 years ago
Special

Ex-Take­da ex­ec hits the ground run­ning at the helm of rare dis­ease biotech — with 3 pri­or­i­ties off the bat; ...

4 years ago
Peer Review

The 20(+1) un­der 40: Your guide to the next gen­er­a­tion of biotech lead­ers

4 years ago
Special

BeiGene/No­var­tis tout new PD-1 da­ta; No­var­tis plans down­siz­ing in Tokyo

4 years ago
News Briefing

En­do reach­es opi­oid set­tle­ment in Flori­da; De­moc­rats call on CMS to low­er pre­mi­ums fol­low­ing Aduhelm price cut

4 years ago
News Briefing

Se­lec­ta turns to syn­bio play­er for $1.1B cap­sid deal; BioN­Tech signs $790M im­munother­a­py deal

4 years ago
News Briefing

2021's NDA list in­cludes some ex­tra­or­di­nary ac­com­plish­ments in year #2 of the pan­dem­ic

4 years ago
Special

End­points ed­i­tors se­lect the top trends of 2022: M&A looks hot as IPOs wane, it's time to see some hard da­ta on AI ...

4 years ago
Editor's note
Special

Spe­cial re­port: Meet 20 ex­tra­or­di­nary women who are su­per­charg­ing bio­phar­ma R&D

4 years ago
People
Special

Pierre Beau­rang hits the ground run­ning at his 3rd start­up; Mike Grey poach­es Astel­las deal­mak­er to head pro­tein ...

4 years ago
Peer Review

ARCH-backed SciNeu­ro kicks off search for CNS au­toan­ti­bod­ies with new deal; Mer­ck + Gilead an­nounce PhII tri­al for ...

4 years ago
News Briefing

Flag­ship keeps ex-FDA com­mish Stephen Hahn busy with an­oth­er CMO gig; Daphne Koller makes key hire at in­sitro by ...

4 years ago
Peer Review

Zio­pharm finds new CEO af­ter six-month search; CFO tran­si­tion at Lon­za to take place in De­cem­ber

4 years ago
Peer Review

From bench to board­room: 20 of the most in­flu­en­tial bio­phar­ma R&D ex­ec­u­tives in drug de­vel­op­ment

4 years ago
People
R&D

As­traZeneca pro­motes on­col­o­gy ex­ec to CMO; Pfiz­er re­places re­tir­ing chief deal­mak­er as war chest ex­pands

4 years ago
Peer Review

Soros, Gates back medtech's move in­to a 'so­cial en­ter­prise'; Ag­ing an­ti-re­jec­tion drug earns fresh ap­proval

4 years ago
News Briefing

Chemo­Cen­tryx gets new PDU­FA date af­ter ma­jor amend­ment; Nim­i­um launch­es with eye on obe­si­ty

4 years ago
News Briefing

As Hutchmed awaits FDA ap­proval for su­r­u­fa­tinib, drug gets the go-ahead in Chi­na; SCO­TUS knocks back last Amarin ...

4 years ago
News Briefing

Two months af­ter ink­ing a SPAC deal, Ren­o­va­cor taps new CMO; Cure­Vac reels in a new de­vel­op­ment chief from Mer­ck KGaA

4 years ago
Peer Review

New da­ta point to how Keytru­da changed lung can­cer treat­ment; A Hous­ton biotech earns ear­ly back­ers in quest to turn ...

5 years ago
News Briefing

Lega­cies: 60 bio­phar­ma pi­o­neers over 60 who helped birth a tech rev­o­lu­tion in the mak­ing

5 years ago
People
Special

The 20(+1) un­der 40: In­side the next gen­er­a­tion of biotech lead­ers

5 years ago
Special

Diem Nguyen tapped to lead 'point of in­flec­tion' at Xalud Ther­a­peu­tics; Di­ana Es­co­lar dances her way to Avro­bio CMO

5 years ago
Peer Review
First page Previous page 10111213141516 Next page Last page
A service from the Financial Times